SCHEMBL1141769

SCHEMBL1141769

CC(C)(C)OC(=O)NC(C)(C)c1ccc(-c2ccc3[nH]nc(CO)c3c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.46
PRKAA1 Q13131 2/20 0.41
PRKAG1 P54619 1/20 0.41
PRKAB1 Q9Y478 1/20 0.41
GSK3B P49841 5/20 0.39
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRA6 Q16445 1/20 0.39
GSK3A P49840 2/20 0.38
DYRK1A Q13627 8/20 0.38
JAK3 P52333 2/20 0.36
MAP4K4 O95819 3/20 0.36
CLK2 P49760 3/20 0.36
DYRK3 O43781 2/20 0.36
CDK1 P06493 2/20 0.36
CDK2 P24941 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1141424 0.85 JAK2 (0.48) JAK2PRKAA1PRKAG1PRKAB1GSK3B
SCHEMBL1141533 0.84 GSK3B (0.48) JAK2PRKAA1PRKAG1PRKAB1GSK3B
SCHEMBL1141675 0.84 PRKAA1 (0.58) JAK2PRKAA1PRKAG1PRKAB1GSK3B
SCHEMBL3781571 0.83 JAK2 (0.46) JAK2PRKAA1PRKAG1PRKAB1GSK3B
SCHEMBL1141348 0.83 JAK2 (0.46) JAK2PRKAA1PRKAG1PRKAB1GSK3B
SCHEMBL1141610 0.83 JAK2 (0.51) JAK2PRKAA1PRKAG1PRKAB1GSK3B
SCHEMBL1141213 0.82 JAK2 (0.47) JAK2PRKAA1PRKAG1PRKAB1GSK3B
SCHEMBL27722694 0.81 JAK2 (0.44) JAK2PRKAA1PRKAG1PRKAB1GSK3B
SCHEMBL1142174 0.81 JAK2 (0.43) JAK2PRKAA1PRKAG1PRKAB1GSK3B
SCHEMBL12009240 0.81 JAK2 (0.43) JAK2PRKAA1PRKAG1PRKAB1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232308-B2 Methods for treating a disease in which Rho kinase is involved UBE INDUSTRIES, LTD. (JP) 2012-07-31 US disclosed
US-8232308-B2 Methods for treating a disease in which Rho kinase is involved UBE INDUSTRIES, LTD. (JP) 2012-07-31 US disclosed
EP-2468729-A1 Novel indazole derivative UBE INDUSTRIES, LTD. (JP) 2012-06-27 EP disclosed
EP-2468729-A1 Novel indazole derivative UBE INDUSTRIES, LTD. (JP) 2012-06-27 EP disclosed
US-20110039891-A1 Methods for treating a disease in which Rho kinase is involved UBE INDUSTRIES, LTD. (JP) 2011-02-17 US disclosed
US-20110039891-A1 Methods for treating a disease in which Rho kinase is involved UBE INDUSTRIES, LTD. (JP) 2011-02-17 US disclosed
US-7855222-B2 Methods for treating a disease in which Rho kinase is involved UBE INDUSTRIES, LTD. (JP) 2010-12-21 US disclosed
US-7855222-B2 Methods for treating a disease in which Rho kinase is involved UBE INDUSTRIES, LTD. (JP) 2010-12-21 US disclosed
US-7855222-B2 Methods for treating a disease in which Rho kinase is involved UBE INDUSTRIES, LTD. (JP) 2010-12-21 US disclosed
CN-1863779-B indazole derivatives UBE INDUSTRIES 2010-05-05 CN disclosed
US-20090264468-A1 Methods for treating a disease in which Rho kinase is involved UBE INDUSTRIES, LTD. (JP) 2009-10-22 US disclosed
US-20090264468-A1 Methods for treating a disease in which Rho kinase is involved UBE INDUSTRIES, LTD. (JP) 2009-10-22 US disclosed
US-20090264468-A1 Methods for treating a disease in which Rho kinase is involved UBE INDUSTRIES, LTD. (JP) 2009-10-22 US disclosed
US-7563906-B2 Indazole derivatives UBE INDUSTRIES, LTD. (JP) 2009-07-21 US disclosed
US-7563906-B2 Indazole derivatives UBE INDUSTRIES, LTD. (JP) 2009-07-21 US disclosed
US-7563906-B2 Indazole derivatives UBE INDUSTRIES, LTD. (JP) 2009-07-21 US disclosed
US-20070129404-A1 Novel indazole derivatives UBE INDUSTRIES, LTD. (JP) 2007-06-07 US disclosed
US-20070129404-A1 Novel indazole derivatives UBE INDUSTRIES, LTD. (JP) 2007-06-07 US disclosed
CN-1863779-A Novel indazole derivative UBE INDUSTRIES (JP) 2006-11-15 CN disclosed
EP-1679308-A1 NOVEL INDAZOLE DERIVATIVE Ube Industries, Ltd. (JP) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264468-A1 Methods for treating a disease in which Rho kinase is involved RHOA, ROCK1, RHOT2 JAK2 313/4885PRKAA1 309/4885PRKAG1 577/4885
US-20070129404-A1 Novel indazole derivatives CIT, ROCK1, ROCK2 JAK2 629/4885PRKAA1 351/4885PRKAG1 442/4885
US-20110039891-A1 Methods for treating a disease in which Rho kinase is involved RHOA, ROCK1, ROCK2 JAK2 317/4885PRKAA1 332/4885PRKAG1 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.